{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:12:24Z","timestamp":1778739144930,"version":"3.51.4"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although myelosuppression is its common dose-limiting toxicity, oxaliplatin-induced immune thrombocytopenia (OITP), a rare and potentially fatal type II hypersensitivity reaction, is often misdiagnosed as ordinary myelosuppression due to insufficient clinical awareness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Relevant literature published up to December 31, 2025 were retrieved from databases including PubMed, Scopus, Embase, Web of Science, Cochrane Library, Wanfang Medical Database and China National Knowledge Infrastructure (CNKI). Cases confirmed as OITP were strictly screened for retrospective analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 40 included patients, the median age was 59 years (range, 36\u201383 years), with a significant female predominance (65.0%). The main primary disease was colorectal cancer (92.5%), and the most commonly used chemotherapy regimen was FOLFOX (77.5%). OITP onset was characterized by a distinct latent period, with a median time to onset of the 9th chemotherapy cycle (range, 2\u201328 cycles). The clinical manifestations were severe: 82.5% of patients had a platelet count drop to &amp;lt; 25\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L, with a median nadir of only 6\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L. Bleeding symptoms were evident in 65.0% of patients, and 52.5% of patients had accompanying systemic hypersensitivity symptoms such as fever and chills. Immunological tests showed that oxaliplatin-dependent platelet antibodies were detected in 48.4% of patients. In terms of treatment, oxaliplatin was discontinued in all patients (100%), combined with platelet transfusion (62.5%), glucocorticoids (55.0%), intravenous immunoglobulin (20.0%) and plasma exchange (12.5%). The overall recovery rate was 92.5%, with a median recovery time of 7 days, and the mortality rate reached 7.5%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>OITP is a severe immune complication occurring after cumulative exposure to oxaliplatin, often accompanied by systemic allergic symptoms. Clinicians should be alert to sudden severe thrombocytopenia after long-term oxaliplatin administration, and permanent discontinuation of oxaliplatin is strongly advised once OITP is diagnosed. In clinical practice, glucocorticoids and platelet transfusion are the main empirical treatment options for OITP, and plasma exchange may be a potential empirical salvage intervention for patients with refractory or life-threatening OITP, while the efficacy of these treatments has not been validated by comparative data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1809508","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:34:07Z","timestamp":1778736847000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics, treatment, and outcomes of Oxaliplatin-induced immune thrombocytopenia"],"prefix":"10.3389","volume":"17","author":[{"given":"Nan","family":"Huang","sequence":"first","affiliation":[{"name":"Clinical Pharmacy, The Central Hospital of Xiangtan, The Affiliated Hospital of Hunan University","place":["Xiangtan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, The Central Hospital of Xiangtan, The Affiliated Hospital of Hunan University","place":["Xiangtan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronghui","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, The Central Hospital of Xiangtan, The Affiliated Hospital of Hunan University","place":["Xiangtan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Lei","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, The Central Hospital of Xiangtan, The Affiliated Hospital of Hunan University","place":["Xiangtan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy, The Central Hospital of Xiangtan, The Affiliated Hospital of Hunan University","place":["Xiangtan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1159\/000518650","article-title":"Oxaliplatin and 5-fluorouracil in advanced well-differentiated digestive neuroendocrine tumors: A multicenter national retrospective study from the French Group of Endocrine Tumors","volume":"112","author":"Girot","year":"2022","journal-title":"Neuroendocrinology"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0753-3322(03)00027-1","article-title":"A molecular biological study of anti-tumor mechanisms of an anti-cancer agent oxaliplatin against established human gastric cancer cell lines","volume":"57","author":"Eriguchi","year":"2003","journal-title":"Biomedicine Pharmacotherapy = Biomedecine Pharmacotherapie"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25369","article-title":"Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil\/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer","volume":"128","author":"Ducreux","year":"2011","journal-title":"Int J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3109\/07357907.2015.1104689","article-title":"XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis","volume":"34","author":"Guo","year":"2016","journal-title":"Cancer Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/01480545.2023.2217700","article-title":"The incidence rate of allergic reactions induced by oxaliplatin is higher in patients with rectal cancer compared with colon cancer","volume":"47","author":"Liu","year":"2024","journal-title":"Drug Chem Toxicol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2006.01.001","article-title":"Oxaliplatin-related neurotoxicity: How and why","volume":"59","author":"Pasetto","year":"2006","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14112465","article-title":"Sex and circadian timing modulate oxaliplatin hematological and hematopoietic toxicities","volume":"14","author":"Dulong","year":"2022","journal-title":"Pharmaceutics"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds074","article-title":"Oxaliplatin-related thrombocytopenia","volume":"23","author":"Jardim","year":"2012","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.154056","article-title":"Oxaliplatin-induced acute thrombocytopenia","volume":"12","author":"Erdem","year":"2016","journal-title":"J Cancer Res Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20516","article-title":"Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin","volume":"81","author":"Curtis","year":"2006","journal-title":"Am J Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.04373.x","article-title":"Oxaliplatin-induced immune pancytopenia","volume":"45","author":"Taleghani","year":"2005","journal-title":"Transfusion"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.06.021","article-title":"Allergic-type reactions to oxaliplatin: Retrospective analysis of 42 patients","volume":"41","author":"Maindrault-Goebel","year":"2005","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.02.001","article-title":"Oxaliplatin immune-induced syndrome occurs with cumulative administration and rechallenge: Single institution series and systematic review study","volume":"15","author":"Bencardino","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14974","article-title":"Oxaliplatin immune-mediated thrombocytopenia: Is there a role for premedication or desensitization","volume":"88","author":"Gal","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyq162","article-title":"Sudden-onset pancytopenia with intracranial hemorrhage after oxaliplatin treatment: A case report and literature review","volume":"41","author":"Teng","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2017.1419600","article-title":"A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia","volume":"23","author":"Curtis","year":"2018","journal-title":"Hematol (Amsterdam Netherlands)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105728","article-title":"Type II hypersensitivity reactions after oxaliplatin rechallenge can be life threatening","volume":"74","author":"Vyskocil","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.12890\/2024_004782","article-title":"Oxaliplatin-induced immune thrombocytopenia in a patient with pancreatic cancer","volume":"11","author":"\u015eent\u00fcrk","year":"2024","journal-title":"Eur J Case Rep Internal Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1700\/1430.15831","article-title":"Acute immune hematological complication of oxaliplatin. A series of 3 cases","volume":"100","author":"Garciaz","year":"2014","journal-title":"Tumori"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/030089161009600125","article-title":"Acute immune-mediated thrombocytopenia due to oxaliplatin administration: A case report","volume":"96","author":"Pietrantonio","year":"2010","journal-title":"Tumori"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.11.005","article-title":"Acute oxaliplatin-induced hemolytic anemia, thrombocytopenia, and renal failure: Case report and a literature review","volume":"16","author":"Phull","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/2054270414531126","article-title":"Antiplatelet antibodies in oxaliplatin-induced immune thrombocytopenia","volume":"5","author":"Mittal","year":"2014","journal-title":"JRSM Open"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000495032","article-title":"Case report: Oxaliplatin-induced immune-mediated thrombocytopenia","volume":"11","author":"Pan","year":"2018","journal-title":"Case Rep Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2025.03.427","article-title":"Drug-induced immune thrombocytopenia: When both oxaliplatin and methylprednisolone are the culprits","volume":"46","author":"Therme","year":"2025","journal-title":"La Rev Medecine Interne"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2013.09.002","article-title":"Fatal oxaliplatin-induced thrombotic thrombocytopenic purpura: A case report","volume":"12","author":"Baretta","year":"2013","journal-title":"Clin Colorectal Cancer"},{"key":"B27","article-title":"Fatal thrombocytopenia after oxaliplatin-based chemotherapy","volume":"28","author":"Shao","year":"2008","journal-title":"Anticancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-3-12","article-title":"Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: Two case reports and a review of the literature","volume":"3","author":"Bautista","year":"2010","journal-title":"J Hematol Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02600.x","article-title":"Immune-mediated pancytopenia induced by oxaliplatin: A case report","volume":"50","author":"Font\u00e3o-Wendel","year":"2010","journal-title":"Transfusion"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/02841860801978913","article-title":"Life-threatening oxaliplatin-induced acute thrombocytopenia, hemolysis and bleeding: A case report","volume":"47","author":"Santodirocco","year":"2008","journal-title":"Acta Oncol (Stockholm Sweden)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.68621","article-title":"Oxaliplatin antibody-related thrombocytopenia: A case report","volume":"16","author":"Pyai","year":"2024","journal-title":"Cureus"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.5045\/br.2014.49.1.61","article-title":"A case of oxaliplatin-induced immune-mediated thrombocytopenia","volume":"49","author":"Suh","year":"2014","journal-title":"Blood Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/1078155210381287","article-title":"Oxaliplatin-induced acute thrombocytopenia","volume":"17","author":"Mason","year":"2011","journal-title":"J Oncol Pharm Pract"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/02841860152703553","article-title":"Oxaliplatin-induced haematological emergency with an immediate severe thrombocytopenia and haemolysis","volume":"40","author":"S\u00f8rbye","year":"2001","journal-title":"Acta Oncol (Stockholm Sweden)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0675-5","article-title":"Oxaliplatin-induced immune mediated thrombocytopenia","volume":"62","author":"Beg","year":"2008","journal-title":"Cancer Chemotherapy Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2014.052","article-title":"Oxaliplatin-induced immune-mediated thrombocytopenia: A case report","volume":"47","author":"Woo","year":"2015","journal-title":"Cancer Res Treat"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1177\/1078155213520262","article-title":"Oxaliplatin-induced immune-mediated cytopenias: A case report and literature review","volume":"21","author":"Forcello","year":"2015","journal-title":"J Oncol Pharm Pract"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2020.07.007","article-title":"Oxaliplatin-induced immune thrombocytopenia: A case report and literature review","volume":"20","author":"Stack","year":"2021","journal-title":"Clin Colorectal Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/000313481107700106","article-title":"Oxaliplatin-induced immune thrombocytopenia in a patient with colon cancer","volume":"77","author":"Akdeniz","year":"2011","journal-title":"Am Surgeon"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2009.n.037","article-title":"Oxaliplatin-induced immune thrombocytopenia: Another cumulative dose-dependent side effect","volume":"8","author":"James","year":"2009","journal-title":"Clin Colorectal Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/s0399-8320(06)73320-6","article-title":"Oxaliplatin-induced immune thrombocytopenia","volume":"30","author":"Pavic","year":"2006","journal-title":"Gastroenterologie Clinique Biologique"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.42.5082","article-title":"Oxaliplatin-induced thrombotic thrombocytopenic purpura: Case report and literature review","volume":"30","author":"Niu","year":"2012","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s1533-0028(11)70349-8","article-title":"Oxaliplatin-mediated autoimmune thrombocytopenia","volume":"8","author":"Saif","year":"2009","journal-title":"Clin Colorectal Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nrc1529","article-title":"Timeline: Chemotherapy and the war on cancer","volume":"5","author":"Chabner","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00880","article-title":"Emerging concepts in immune thrombocytopenia","volume":"9","author":"Swinkels","year":"2018","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/bjh.19070","article-title":"Complement in immune thrombocytopenia (ITP): The role of complement in refractory ITP","volume":"203","author":"Weitz","year":"2023","journal-title":"Br J Haematol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000574","article-title":"Immune thrombocytopenia: Recent advances in pathogenesis and treatments","volume":"5","author":"Audia","year":"2021","journal-title":"HemaSphere"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-11_part_1-199812010-00009","article-title":"Drug-induced thrombocytopenia: A systematic review of published case reports","volume":"129","author":"George","year":"1998","journal-title":"Ann Internal Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279484","article-title":"Treatment of drug-induced immune thrombocytopenias","volume":"107","author":"Marini","year":"2022","journal-title":"Haematologica"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03360.x","article-title":"Drug-induced immune thrombocytopenia: Pathogenesis, diagnosis, and management","volume":"7","author":"Aster","year":"2009","journal-title":"J Thromb Haemostasis: JTH"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1001\/jama.232.7.744","article-title":"Editorial: Wet purpura, dry purpura","volume":"232","author":"Crosby","year":"1975","journal-title":"Jama"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1605690","article-title":"Oxaliplatin-induced type II hypersensitivity in colorectal cancer: a cohort study on clinical presentation, diagnosis, and management","volume":"16","author":"V\u00e1zquez-Revuelta","year":"2025","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1809508\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:34:08Z","timestamp":1778736848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1809508\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2026.1809508"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1809508","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"article-number":"1809508"}}